FOCUS ISSUE: ATRIAL FIBRILLATION: CLINICAL RESEARCH: ATRIAL FIBRILLATION AND EMBOLISM
Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent ImplantationImplications for Bleeding Risk and Prognosis
Juan M. Ruiz-Nodar, MD, PhD*,
Francisco Marín, MD, PhD , ,
José Antonio Hurtado, MD , ,
José Valencia, MD, PhD*,
Eduardo Pinar, MD, PhD , ,
Javier Pineda, MD, PhD*,
Juan Ramón Gimeno, MD, PhD , ,
Francisco Sogorb, MD, PhD*,
Mariano Valdés, MD, PhD and
Gregory Y.H. Lip, MD, FACC, FESC ,*
* Department of Cardiology, Hospital General Universitario de Alicante, Alicante, Spain
Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
Red de Investigación Cardiovascular RECAVA, Instituto Salud Carlos III, Madrid, Spain
University Department of Medicine, City Hospital, Birmingham, United Kingdom.
Manuscript received August 20, 2007;
revised manuscript received October 29, 2007,
accepted November 20, 2007.
* Reprint requests and correspondence: Dr. Gregory Y. H. Lip, University Department of Medicine, City Hospital, Birmingham B18 7QH, United Kingdom. (Email: g.y.h.lip{at}bham.ac.uk).
Objectives: This study was designed to review outcomes in relation to antithrombotic therapy management strategies for patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) with stenting.
Background: There is limited evidence on the optimal antithrombotic therapy management strategies for patients with AF who undergo PCI with stenting.
Methods: We reviewed 426 patients (70.9% men, mean age 71.5 ± 8.5 years) with AF undergoing PCI with stenting between 2001 and 2006. We recorded clinical and demographic characteristics of the patients, stroke risk factors, and antithrombotic therapy use before PCI and at discharge. Clinical follow-up was performed, and all bleeding episodes, thromboembolism, and major adverse cardiac events (MACE) (i.e., death, acute myocardial infarction, or target lesion revascularization) were recorded.
Results: The most commonly associated comorbidities were hypertension (74.5%), diabetes mellitus (40.2%), chronic renal failure (14.9%), and congestive heart failure (26.7%); 80% of patients had 2 stroke risk factors. Of the drugs prescribed at discharge, aspirin plus clopidogrel were used in 174 patients (40.8%), whereas 213 patients (50%) were discharged with triple therapy (coumarins, aspirin, and clopidogrel). Complete follow-up was achieved in 87.5% (median 594 days; range 0 to 2,190). The incidence of adverse events was high (36.6%), with major bleeding in 12.3%, thromboembolic events in 4.2%, and MACE in 32.3%. All-cause mortality was high (22.6%). In a multivariate analysis, non-anticoagulation with coumarins increased mortality (17.8% vs. 27.8%; hazard ratio [HR] = 3.43; 95% confidence interval [CI] 1.61 to 7.54; p = 0.002) and MACE (26.5% vs. 38.7%; HR = 4.9; 95% CI 2.17 to 11.1; p < 0.01) In a Cox-regression analysis, non-anticoagulation (p < 0.01) and age (p = 0.02) were independent predictors of MACE.
Conclusions: Patients with AF undergoing PCI with stenting represent a high-risk population because of age, comorbidities, and presence of stroke risk factors. These patients have a high mortality and MACE rate, which is reduced by anticoagulation therapy.
|
Abbreviations and Acronyms
| | ACS = acute coronary syndrome | | AF = atrial fibrillation | | DES = drug-eluting stent(s) | | MACE = major adverse cardiac events | | MAE = major adverse events | | PCI = percutaneous coronary intervention |
|
Related Articles
-
"Triple Therapy" or Triple Threat?: Balancing the Risks of Antithrombotic Therapy for Patients With Atrial Fibrillation and Coronary Stents
- Steven Francescone and Jonathan L. Halperin
J. Am. Coll. Cardiol. 2008 51: 826-827.
[Full Text]
[PDF]
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 51: A23-A24.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
F. W. A. Verheugt
Triple Antithrombotic Therapy After Coronary Stenting: Why Expert Opinion Is Necessary
Circ Cardiovasc Interv,
October 1, 2011;
4(5):
410 - 412.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. P. Faxon, J. W. Eikelboom, P. B. Berger, D. R. Holmes Jr, D. L. Bhatt, D. J. Moliterno, R. C. Becker, and D. J. Angiolillo
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting: A North American Perspective: Executive Summary
Circ Cardiovasc Interv,
October 1, 2011;
4(5):
522 - 534.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. D. Ezekowitz, T. H. Aikens, R. Nagarakanti, and T. Shapiro
Atrial Fibrillation: Outpatient Presentation and Management
Circulation,
July 5, 2011;
124(1):
95 - 99.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Ruiz-Nodar, F. Marin, S. Manzano-Fernandez, J. Valencia-Martin, J. A. Hurtado, V. Roldan, J. Pineda, E. Pinar, F. Sogorb, M. Valdes, et al.
An Evaluation of the CHADS2 Stroke Risk Score in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Revascularization
Chest,
June 1, 2011;
139(6):
1402 - 1409.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Rubboli, J. C. Kovacic, R. Mehran, and G. Y. H. Lip
Coronary Stent Implantation in Patients Committed to Long-term Oral Anticoagulation Therapy: Successfully Navigating the Treatment Options
Chest,
May 1, 2011;
139(5):
981 - 987.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ghattas, E. Shantsila, and G. Y. H. Lip
Antithrombotic therapy after percutaneous coronary intervention in anticoagulated patients: a fine balance between thrombosis and bleeding
Therapeutic Advances in Cardiovascular Disease,
February 1, 2011;
5(1):
5 - 9.
[PDF]
|
 |
|

|
 |

|
 |
 
H.-J. Zhao, Z.-T. Zheng, Z.-H. Wang, S.-H. Li, Y. Zhang, M. Zhong, and W. Zhang
"Triple Therapy" Rather Than "Triple Threat": A Meta-analysis of the Two Antithrombotic Regimens After Stent Implantation in Patients Receiving Long-term Oral Anticoagulant Treatment
Chest,
February 1, 2011;
139(2):
260 - 270.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. P. Singh, M. Singh, U. Bedi, J. Molnar, R. Arora, and S. Khosla
Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation
Therapeutic Advances in Cardiovascular Disease,
February 1, 2011;
5(1):
23 - 31.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
L. B. Goldstein, C. D. Bushnell, R. J. Adams, L. J. Appel, L. T. Braun, S. Chaturvedi, M. A. Creager, A. Culebras, R. H. Eckel, R. G. Hart, et al.
Guidelines for the Primary Prevention of Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke,
February 1, 2011;
42(2):
517 - 584.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Hansen, R. Sorensen, M. T. Clausen, M. L. Fog-Petersen, J. Raunso, N. Gadsboll, G. H. Gislason, F. Folke, S. S. Andersen, T. K. Schramm, et al.
Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation
Arch Intern Med,
September 13, 2010;
170(16):
1433 - 1441.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Y. H. Lip, K. Huber, F. Andreotti, H. Arnesen, J. K. Airaksinen, T. Cuisset, P. Kirchhof, and F. Marin
Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Eur. Heart J.,
June 1, 2010;
31(11):
1311 - 1318.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. T. Ko, L. Yun, H. C. Wijeysundera, C. A. Jackevicius, S. V. Rao, P. C. Austin, J. F. Marquis, and J. V. Tu
Incidence, Predictors, and Prognostic Implications of Hospitalization for Late Bleeding After Percutaneous Coronary Intervention for Patients Older Than 65 Years
Circ Cardiovasc Interv,
April 1, 2010;
3(2):
140 - 147.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. Piccini, A. F. Hernandez, X. Zhao, M. R. Patel, W. R. Lewis, E. D. Peterson, G. C. Fonarow, and Get With The Guidelines Steering Committee and Hos
Quality of Care for Atrial Fibrillation Among Patients Hospitalized for Heart Failure
J. Am. Coll. Cardiol.,
September 29, 2009;
54(14):
1280 - 1289.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A Sambola, I Ferreira-Gonzalez, J Angel, F Alfonso, J Maristany, O Rodriguez, H Bueno, J R Lopez-Minguez, J Zueco, F Fernandez-Aviles, et al.
Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study
Heart,
September 15, 2009;
95(18):
1483 - 1488.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D. Lopes, L. E. Elliott, H. D. White, J. S. Hochman, F. Van de Werf, D. Ardissino, T. T. Nielsen, W. D. Weaver, P. Widimsky, P. W. Armstrong, et al.
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial
Eur. Heart J.,
August 2, 2009;
30(16):
2019 - 2028.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Schomig, N. Sarafoff, and M. Seyfarth
Triple antithrombotic management after stent implantation: when and how?
Heart,
August 1, 2009;
95(15):
1280 - 1285.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R. Holmes Jr, D. J. Kereiakes, N. S. Kleiman, D. J. Moliterno, G. Patti, and C. L. Grines
Combining Antiplatelet and Anticoagulant Therapies
J. Am. Coll. Cardiol.,
July 7, 2009;
54(2):
95 - 109.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Marin, P. Kirchhof, and G. Y.H. Lip
Antithrombotic therapy use for patients with atrial fibrillation undergoing percutaneous coronary intervention: new data in an area of limited evidence
Europace,
July 1, 2009;
11(7):
842 - 843.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Crandall, D. J. Bradley, D. L. Packer, and S. J. Asirvatham
Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies
Mayo Clin. Proc.,
July 1, 2009;
84(7):
643 - 662.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
APPRAISE Steering Committee and Investigators
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
Circulation,
June 9, 2009;
119(22):
2877 - 2885.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Prasad and D. R Holmes
Update on dual antiplatelet therapy for percutaneous coronary intervention
Heart,
June 1, 2009;
95(11):
861 - 865.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Schmitt, G. Duray, B. J. Gersh, and S. H. Hohnloser
Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications
Eur. Heart J.,
May 1, 2009;
30(9):
1038 - 1045.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Ruiz-Nodar, F. Marin, J. Sanchez-Paya, J. A. Hurtado, J. Valencia-Martin, S. Manzano-Fernandez, V. Roldan, V. Perez-Andreu, F. Sogorb, M. Valdes, et al.
Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation
Eur. Heart J.,
April 2, 2009;
30(8):
932 - 939.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Koul and D. J. Moliterno
Bare-Metal Versus Drug-Eluting Stent Placement Among Patients Presenting With Anemia
J. Am. Coll. Cardiol. Intv.,
April 1, 2009;
2(4):
337 - 338.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Manzano-Fernandez, F. Marin, F. J. Pastor-Perez, C. Caro, F. Cambronero, J. Lacunza, E. Pinar, D. A. Pascual-Figal, M. Valdes, and G. Y. H. Lip
Impact of Chronic Kidney Disease on Major Bleeding Complications and Mortality in Patients With Indication for Oral Anticoagulation Undergoing Coronary Stenting
Chest,
April 1, 2009;
135(4):
983 - 990.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sourgounis, J. Lipiecki, T. S. Lo, and M. Hamon
Coronary Stents and Chronic Anticoagulation
Circulation,
March 31, 2009;
119(12):
1682 - 1688.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al.
Highlights of the Year in JACC 2008
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
373 - 398.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst
CHAPTER 29 Atrial Fibrillation
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Ohmori, Y. Yano, K. Shimada, K. Kario, and Y. Sakata
Is thrombogenesis related to residual platelet function in ischaemic heart disease?: reply
Eur. Heart J.,
December 2, 2008;
29(24):
3065 - 3066.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Y H Lip
Managing the anticoagulated patient with atrial fibrillation at high risk of stroke who needs coronary intervention
BMJ,
September 12, 2008;
337(sep12_1):
a840 - a840.
[Full Text]
|
 |
|

|
 |

|
 |
 
S. Manzano-Fernandez, F. J. Pastor, F. Marin, F. Cambronero, C. Caro, D. A. Pascual-Figal, I. P. Garrido, E. Pinar, M. Valdes, and G. Y. H. Lip
Increased Major Bleeding Complications Related to Triple Antithrombotic Therapy Usage in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Artery Stenting
Chest,
September 1, 2008;
134(3):
559 - 567.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H. Hohnloser, G. Z. Duray, U. Baber, and J. L. Halperin
Prevention of stroke in patients with atrial fibrillation: current strategies and future directions
Eur. Heart J. Suppl.,
September 1, 2008;
10(suppl_H):
H4 - H10.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Ruiz-Nodar, F. Marin, and G. Y.H. Lip
Antithrombotic Therapy Use After Percutaneous Coronary Intervention and Stent Implantation in Patients Taking Chronic Oral Anticoagulation
J. Am. Coll. Cardiol. Intv.,
June 1, 2008;
1(3):
329 - 329.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Rogacka, A. Chieffo, and A. Colombo
Reply
J. Am. Coll. Cardiol. Intv.,
June 1, 2008;
1(3):
330 - 331.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A J. Hermosillo and S. A Spinler
Aspirin, Clopidogrel, and Warfarin: Is the Combination Appropriate and Effective or Inappropriate and Too Dangerous?
Ann. Pharmacother.,
June 1, 2008;
42(6):
790 - 805.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Francescone and J. L. Halperin
"Triple Therapy" or Triple Threat?: Balancing the Risks of Antithrombotic Therapy for Patients With Atrial Fibrillation and Coronary Stents
J. Am. Coll. Cardiol.,
February 26, 2008;
51(8):
826 - 827.
[Full Text]
[PDF]
|
 |
|
|